Diffusion Pharmaceuticals
300 East Main Stree, Suite 201
Charlottesville
Virginia
22902
United States
Tel: 434-220-0718
Fax: 434-220-0722
Website: http://www.diffusionpharma.com/
141 articles about Diffusion Pharmaceuticals
-
Diffusion Pharma Provides Corporate Highlights And Reports Financial First Quarter 2017 Results
5/16/2017
-
Diffusion Pharma Awarded U.S. Patent For TSC As Therapeutic In Five Hypoxia-Related Indications
4/4/2017
-
Diffusion Pharma Announces Closing Of Oversubscribed Private Placement
4/3/2017
-
Diffusion Pharma Provides Corporate Highlights And Reports 2016 Financial Results
3/31/2017
-
Diffusion Pharma’ TSC Phase I/II Glioblastoma Multiforme Clinical Trial Results Published In February 2017 Edition Of Journal Of Neurosurgery
2/8/2017
-
Diffusion Pharma Files Definitive Proxy Statement For Upcoming Special Meeting Of Stockholders
12/12/2016
-
Diffusion Pharma Provides Corporate Highlights and Reports Financial Third Quarter 2016 Results
11/14/2016
-
Diffusion Pharma Announces Uplisting To NASDAQ Capital Market
11/8/2016
-
Diffusion Pharma Establishes Scientific Advisory Board
9/29/2016
-
Diffusion Pharma Successfully Completes Animal Toxicity Studies In Preparation For Phase III Pivotal Trial Of TSC In New Diagnosed Glioblastoma Patients
9/19/2016
-
Diffusion Pharma To Present At 18th Annual Rodman & Renshaw Global Investment Conference
9/9/2016
-
Diffusion Pharma Announces Reverse Stock Split In Preparation For Proposed Uplisting To NASDAQ Capital Market
8/18/2016
-
Diffusion Pharma Announces Acceptance Of Abstract On Use Of TSC In Hypoxia Driven Medical Emergencies At ACEP 2016 Research Forum
7/6/2016
-
RestorGenex and Diffusion Pharma Merge to Form Wholly-Owned Oncology Subsidiary
12/28/2015
-
Diffusion Pharmaceuticals To Present At Cavendish Global Health Impact Forum
10/30/2014
-
Diffusion Pharmaceuticals Clinical Trial Of TSC In Brain Cancer Reaches One Year Interim Endpoint
5/15/2014
-
Diffusion Pharmaceuticals Closes $5 Million Financing; Completes Enrollment and Dosing in Phase 2 Trial In Brain Cancer
6/20/2013
-
Diffusion Pharmaceuticals Receives FDA Orphan Designation for TSC, a First-in-Class Drug for the Treatment of Metastatic Brain Cancer
12/11/2012
-
Diffusion Pharmaceuticals Successfully Completes Phase I Brain Cancer Trial
11/20/2012
-
Diffusion Pharmaceuticals Closes on $5 Million Financing; Continues Phase 2 Clinical Trial In Primary Brain Cancer
9/17/2012